Boston, Mass., and Seattle, Wash., – January 5, 2023 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 8:00 a.m. Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel.
“Affini-T has had a number of successes this past year from our launch co-led by Vida Ventures and Leaps by Bayer, to our growing team and advancing pipeline,” said Jak Knowles, M.D. “We’re excited to present at this year’s conference and share our progress to date, as well as the programs we’re driving forward that target the most prevalent oncogenic drivers in solid tumor cancers, beginning with KRAS.”
About Affini-T Therapeutics
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.
Affini-T Investor Contact:
Ailsa Dalgliesh, PhD